0
Clinical Investigations: ASTHMA |

Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids*

Andrew M. Wilson, MD; Owen J. Dempsey, MD; Erika J. Sims, BSc; Brian J. Lipworth, MD
Author and Funding Information

*From the Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK.

Correspondence to: Brian J. Lipworth, MD, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland DD1 9SY, UK



Chest. 2001;119(4):1021-1026. doi:10.1378/chest.119.4.1021
Text Size: A A A
Published online

Objective: To assess the addition of a leukotriene receptor antagonist and a long-acting β2-agonist as second-line therapy in asthma.

Design: Placebo-controlled, double-dummy, crossover study.

Setting: Outpatient clinic.

Patients: Twenty patients with persistent asthma not controlled with inhaled corticosteroid therapy.

Interventions: Montelukast, 10 mg once daily, or salmeterol, 50 μg bid, each for 2 weeks with 1-week run-in and washout placebo periods.

Measurements and results: Adenosine monophosphate (AMP) bronchial challenge, blood eosinophil count (EOS), exhaled nitric oxide, and lung function after both placebo periods and after the first and last doses of each active treatment. Patients recorded their domiciliary peak expiratory flow (PEF), asthma symptoms, and rescue bronchodilator requirement (RES) twice daily throughout the study. For the primary end point of the provocative concentration of AMP causing a 20% fall in FEV1, compared to placebo (47.5 ± 13.0 mg/mL), there were significant differences with the first (114.1 ± 36.9 mg/mL) and last (94.2 ± 30.4 mg/mL) doses of montelukast as well as the first (160.1 ± 64.5 mg/mL) but not the last (70.1 ± 23.7 mg/mL) dose of salmeterol. Only montelukast produced significant suppression of the EOS. Neither drug affected exhaled nitric oxide levels. There were significant improvements with the first doses of salmeterol for all parameters of lung function. After 2 weeks of treatment, there were significant improvements with both drugs for RES and morning PEF. There were no significant differences between drugs for any end points except EOS.

Conclusions: Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy. Montelukast also produced significant effects on AMP challenge and EOS suggesting anti-inflammatory activity.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
Allergic Rhinitis and its Impact on Asthma (ARIA) 2010 revision.
Allergic Rhinitis and its Impact on Asthma Workshop Group | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543